Registered Members Login:
   
Forgotten Your Details? Click Here To Recover +
Welcome To The ShareCafe Community - Talk Shares And Take Stock With Smart Investors - New Here? Click To Register >

4 Pages (Click to Jump) V   1 2 3 4 >

odi01
Posted on: May 31 2020, 03:43 PM


Group: Member
Posts: 772

https://www.fool.com.au/2020/05/31/3-exciti...-buy-next-week/
  Forum: By Share Code

odi01
Posted on: May 28 2020, 07:48 PM


Group: Member
Posts: 772

https://finance.yahoo.com/news/hedge-funds-...;hl=en&sp=1
  Forum: By Share Code

odi01
Posted on: May 25 2020, 04:29 PM


Group: Member
Posts: 772

Clinuvel Pharmaceuticals Limited (ASX: CUV) has seen its short interest slide to 9.3%. This biopharmaceutical companys shares are trading at a premium which some investors appear to believe is excessive.

https://www.fool.com.au/2020/05/25/these-ar...es-25-may-2020/
  Forum: By Share Code

odi01
Posted on: May 25 2020, 02:39 PM


Group: Member
Posts: 772

https://www.livewiremarkets.com/wires/what-...r-avita-medical
  Forum: By Share Code

odi01
Posted on: May 20 2020, 03:40 PM


Group: Member
Posts: 772

https://www.asx.com.au/asx/statistics/displ...;idsId=02236893
  Forum: By Share Code

odi01
Posted on: May 19 2020, 03:25 PM


Group: Member
Posts: 772

Original title: Lecheng to introduce new drug for adult erythropoietic porphyria treatment Source: - Hainan Channel

We have learned from the Boao Leucheng Advanced Zone in Hainan that the Boao Leucheng Wellness Rare Disease Clinical Medical Center and Professor Zhang Xuejun's team at the Boao Super Hospital Dermatology Center will soon introduce the adult erythropoietic porphyria treatment drug SCENESSE? (alfarnitide 16mg) to provide EPP patients in China with a new treatment option that can significantly improve their quality of life.

Erythropoietic protoporphyria (EPP) is a rare disease with an incidence of about 1 in 100,000. This is caused by a mutation in a patient's gene that impairs the activity of iron-chelating enzymes, causing a large accumulation of protoporphyrin Ⅸ in the body. At present, the treatment of EPP in China mainly includes avoiding sunlight, topical use of sunscreen, oral administration of β-carotene or cysteine, and liver transplantation if necessary, the overall treatment effect is very limited.

According to the introduction, on October 8, 2019, the U.S. FDA approved Clinuvel's drug SCENESSE? (afanotide 16mg) through the priority review approval process for the treatment of adult EPP patients with a history of phototoxic reactions to increase their pain-free light exposure time.SCENESSE? was approved based on two multicenter, randomized, double-blind, placebo-controlled Phase III clinical studies. More than 800 patients worldwide have been treated with SCENESSE? in more than 20 clinical studies for different indications, demonstrating that SCENESSE? is well tolerated.

SCENESSE? has been approved in Europe as an orphan drug for the prevention of phototoxic reactions in adult EPP patients since 2014, and since 2010, CLINUVEL has initiated studies on SCENESSE? in vitiligo indications.

SCENESSE? is a melanocortin 1 receptor agonist that provides systemic photoprotection against UV and solar radiation by stimulating increased melanin levels in the skin, thereby providing preventive photoprotection to the skin throughout the body. (Xu Liang)

(Editor: Liu Yang, Chen Haiyan)

https://finance.sina.cn/2020-05-18/detail-i...d.html?from=wap
  Forum: By Share Code

odi01
Posted on: May 16 2020, 03:57 PM


Group: Member
Posts: 772

https://porphyrianews.com/scenesse-china-ep...ients-treatment
  Forum: By Share Code

odi01
Posted on: May 15 2020, 03:02 PM


Group: Member
Posts: 772

http://www.oleantimesherald.com/business/a...b42ac091a8.html
  Forum: By Share Code

odi01
Posted on: May 11 2020, 07:55 PM


Group: Member
Posts: 772

https://www.asx.com.au/asx/statistics/displ...;idsId=02234208
  Forum: By Share Code

odi01
Posted on: May 11 2020, 07:52 PM


Group: Member
Posts: 772

https://in.reuters.com/article/brief-avita-...o-idINL8N2CT1KT
  Forum: By Share Code

odi01
Posted on: May 6 2020, 09:45 PM


Group: Member
Posts: 772

https://www.change.org/p/licht-f%C3%BCr-all...amp;utm_term=cs
  Forum: By Share Code

odi01
Posted on: May 6 2020, 12:34 AM


Group: Member
Posts: 772

https://www.morningstar.com.au/stocks/artic...-on-skin/199295
  Forum: By Share Code

odi01
Posted on: May 3 2020, 02:48 AM


Group: Member
Posts: 772

https://www.fool.com/investing/2020/05/02/x...tial-gains.aspx
  Forum: By Share Code

odi01
Posted on: May 3 2020, 12:34 AM


Group: Member
Posts: 772

Greetings from New York. 12 years ago, Clinuvel had only one substance they wanted to develop a new drug with. The strategy of the company was clearly focused on this task and convinced me. In 2007, I sat for 2 days with the management of the company in Australia and decided to buy shares of the company for 1.75 Euro in a capital increase. The chances of failure at that time were over 90%, because in an early phase of a company things can happen that nobody knows before. The financial crisis of 2008/2009 hit the company very hard, but nevertheless the management never lost focus. The reward for all their efforts was the approval of the drug in Europe. Since 2016 it has been made available to patients here. Tomorrow the company will present itself at a UBS Health Care Conference in New York. If all goes well, the drug will also be approved in the USA on July 8, 2019. This would further double the sales potential, since the US market is about the same size as the European market. This is already partially priced into the company's share price, so that a rejection by the FDA should set the share price back. The share is currently quoted in Frankfurt at just under EUR 20. Of course, after 1.100% performance in 12 years, the question arises as to whether the company would have made a profit if there hadn't been a new, enormous potential on the horizon. The drug could delay the aging process of human skin for years, which could take the company into completely different dimensions in the long term. Of course, the company could still fail, but the risk today, unlike back then, is only 10%.

https://gramho.com/media/2047660873535335550
  Forum: By Share Code

odi01
Posted on: Apr 29 2020, 03:38 PM


Group: Member
Posts: 772

https://www.businesswire.com/news/home/2020...-2020-Financial
  Forum: By Share Code

odi01
Posted on: Apr 23 2020, 04:31 PM


Group: Member
Posts: 772

http://en.winhealth.hk/about_view.aspx?Typ...mp;FId=t1:147:1
  Forum: By Share Code

odi01
Posted on: Apr 22 2020, 05:42 AM


Group: Member
Posts: 772

https://www.smarteranalyst.com/new-blurbs/o...a-medical-rcel/
  Forum: By Share Code

odi01
Posted on: Apr 20 2020, 08:22 PM


Group: Member
Posts: 772

https://www.asx.com.au/asx/statistics/displ...;idsId=02226608
  Forum: By Share Code

odi01
Posted on: Apr 9 2020, 06:13 PM


Group: Member
Posts: 772

https://kalkinemedia.com/au/blog/the-run-up...ealthcare-space
  Forum: By Share Code

odi01
Posted on: Apr 9 2020, 05:45 PM


Group: Member
Posts: 772

https://kalkinemedia.com/au/blog/4-stocks-w...mts-fmg-cuv-evn
  Forum: By Share Code

odi01
Posted on: Apr 9 2020, 05:48 AM


Group: Member
Posts: 772

https://www.morningstar.com.au/stocks/artic...-on-skin/199295
  Forum: By Share Code

odi01
Posted on: Apr 9 2020, 05:45 AM


Group: Member
Posts: 772

https://www.cnbc.com/2020/04/07/cramer-ligh...-at-boeing.html
  Forum: By Share Code

odi01
Posted on: Apr 8 2020, 01:45 AM


Group: Member
Posts: 772

https://kalkinemedia.com/au/blog/the-burgeo...ace-csl-cuv-avh
  Forum: By Share Code

odi01
Posted on: Apr 8 2020, 01:43 AM


Group: Member
Posts: 772

https://kalkinemedia.com/au/blog/the-burgeo...ace-csl-cuv-avh
  Forum: By Share Code

odi01
Posted on: Apr 7 2020, 03:19 PM


Group: Member
Posts: 772

https://www.healio.com/dermatology/skin-car...-protoporphyria
  Forum: By Share Code

odi01
Posted on: Apr 3 2020, 07:03 PM


Group: Member
Posts: 772

https://stockhead.com.au/health/clinuvel-re...ichael-jackson/
  Forum: By Share Code

odi01
Posted on: Apr 3 2020, 03:19 AM


Group: Member
Posts: 772

http://lifelivedfearless.com/pushyourlimit...achievesuccess/
  Forum: By Share Code

odi01
Posted on: Apr 1 2020, 01:59 AM


Group: Member
Posts: 772

CLINUVEL PHARMACEUTICALS

Quality Control

CLINUVEL continuously reviews its operations to evaluate the ongoing supply of SCENESSE®. The synthetic peptide afamelanotide, which is the active ingredient in SCENESSE®, is manufactured in the European Union under current Good Manufacturing Practice (GMP) conditions and is supplied to a contract manufacturer in cold chain transport in the United States. Other synthetic excipients of SCENESSE® are sourced in the USA. Quality control of the drug entering the European Union includes further laboratory testing prior to formal release of the product and controlled distribution to hospitals treating adult patients with erythropoietic protoporphyria (EPP).

Impact Assessment

Due to the procurement, manufacture and controlled distribution of SCENESSE® , there are currently no consequences for CLINUVEL's business activities in the European Economic Area or the USA that could be affected by the COVID 19 outbreaks. The situation will continue to be closely monitored.

Comment

CLINUVEL is aware of the global concern about the spread of coronavirus and its impact on public health," said Dennis Wright, Chief Scientific Officer of CLINUVEL. "As part of our global pharmacovigilance and quality management systems, we have a duty to reassure the medical community. We can offer patients, physicians and other stakeholders the comfort that the current coronavirus outbreak will not affect the provision of SCENESSE® to those in need. “

https://porphyriafoundation.org/for-patient...y-of-treatment/
  Forum: By Share Code

odi01
Posted on: Mar 31 2020, 08:18 PM


Group: Member
Posts: 772

https://www.livewiremarkets.com/wires/the-n...the-market-rout
  Forum: By Share Code

odi01
Posted on: Mar 26 2020, 09:23 PM


Group: Member
Posts: 772

News



EPP in "Corona Times"


As we have been informed by the Board of Directors from the clinics in Berlin, Chemnitz and Düsseldorf, everything is being done to guarantee the treatment of patients at the present time and under the current conditions. As patients have learned from their handlers, certain conditions apply, such as: being "healthy", wearing mouth and nose protection and keeping a distance, as is currently common practice.

http://www.epp-deutschland.de/
  Forum: By Share Code

odi01
Posted on: Mar 21 2020, 12:45 AM


Group: Member
Posts: 772

Coronavirus vaccine: 45 healthy volunteers participate
43-year-old Jennifer Haller was the first volunteer to be injected with a potential vaccine against the novel coronavirus. This is part of the first phase of clinical testing of the vaccine at a research institute in Seattle, the US National Institutes of Health (NIH) announced on Monday. 45 healthy volunteers between 18 and 55 years of age will participate in the test in the coming weeks.

https://www.rtl.de/cms/firma-aus-den-usa-su...ff-4505425.html
  Forum: By Share Code

odi01
Posted on: Mar 5 2020, 05:27 PM


Group: Member
Posts: 772

https://www.businesswire.com/news/home/2020...tudy-Evaluating
  Forum: By Share Code

odi01
Posted on: Mar 4 2020, 03:44 AM


Group: Member
Posts: 772

https://www.ncbi.nlm.nih.gov/pubmed/32118270
  Forum: By Share Code

odi01
Posted on: Mar 4 2020, 03:39 AM


Group: Member
Posts: 772

https://pub.webull.com/us/news-html/d7e230b...lor=1&hl=en
  Forum: By Share Code

odi01
Posted on: Feb 26 2020, 11:37 PM


Group: Member
Posts: 772

https://themarketherald.com.au/clinuvel-pha...ent-2020-02-26/
  Forum: By Share Code

odi01
Posted on: Feb 22 2020, 06:39 AM


Group: Member
Posts: 772

for a better world
Clinuvel is a biopharmaceutical company developing drugs for the treatment of a number of serious skin diseases. My Australian colleagues, among others, drew my attention to this company.
Its lead drug, SCENESSE, is used to treat erythropoietic protoporphyria (EPP). EPP is a rare, lifelong genetic disease characterized by severe skin intolerance to light, leading to unbearable pain, swelling and scarring. People living with EPP must avoid sunlight and often stay indoors. According to the company, approximately 10,000 people worldwide are affected by EPP.
SCENESSE is also used in the treatment of vitiligo, a common skin disease in which the skin's pigment-producing cells are missing. The company estimates that Vitiligo affects between 0.1 and 2% of the world's population (7.6 to 152 million people).
Clinuvel currently has a virtual monopoly. SCENESSE is the only drug approved for the treatment of EPP. The drug is currently approved in the EU and since October last year also in the USA.
The company continues to reinvest its (now very high) profits in new drugs and the research into further fields of application for its current active ingredients. Clinuvel could thus be able to help even more people with other diseases, some of which are serious and currently difficult to cure

https://m.onvista.de/news/3-wenig-bekannte-...-welt-330570623
  Forum: By Share Code

odi01
Posted on: Feb 21 2020, 07:47 PM


Group: Member
Posts: 772

https://youtu.be/dHyuESS9JuQ
  Forum: By Share Code

odi01
Posted on: Feb 21 2020, 07:17 PM


Group: Member
Posts: 772

https://podcasts.google.com/?feed=aHR0cHM6L...AAAAAHQAAAAAQBQ
  Forum: By Share Code

odi01
Posted on: Feb 20 2020, 03:42 PM


Group: Member
Posts: 772

https://www.shortman.com.au/stock?q=CUV
  Forum: By Share Code

odi01
Posted on: Feb 20 2020, 04:51 AM


Group: Member
Posts: 772

http://nabsociety.org/site/?page_id=1095
  Forum: By Share Code

odi01
Posted on: Feb 19 2020, 07:38 PM


Group: Member
Posts: 772

https://kalkinemedia.com/au/blog/how-fda-ap...althcare-stocks
  Forum: By Share Code

odi01
Posted on: Feb 19 2020, 02:13 PM


Group: Member
Posts: 772

https://www.asx.com.au/asx/statistics/displ...;idsId=02203898

https://www.asx.com.au/asx/statistics/displ...;idsId=02203905
  Forum: By Share Code

odi01
Posted on: Feb 16 2020, 07:28 PM


Group: Member
Posts: 772

https://www.eurekareport.com.au/investment-...005759#Clinuvel
  Forum: By Share Code

odi01
Posted on: Feb 16 2020, 12:19 AM


Group: Member
Posts: 772

https://youtu.be/ayjUR6Cghoc
  Forum: By Share Code

odi01
Posted on: Feb 15 2020, 03:35 PM


Group: Member
Posts: 772

https://academic.oup.com/jbcr/article/41/1/215/5642499

https://flashalert.me/?symbol=RCEL&sour...bRdYOj2VdwnuKwa
  Forum: By Share Code

odi01
Posted on: Feb 14 2020, 04:26 PM


Group: Member
Posts: 772

https://www.livewiremarkets.com/wires/buy-h...growth-mid-caps
  Forum: By Share Code

odi01
Posted on: Feb 13 2020, 01:34 PM


Group: Member
Posts: 772

https://www.gurufocus.com/news/1036707/blac...ia-holdings-inc.
  Forum: By Share Code

odi01
Posted on: Feb 11 2020, 06:20 PM


Group: Member
Posts: 772

https://www.livewiremarkets.com/wires/polyn...urns-innovators
  Forum: By Share Code

odi01
Posted on: Feb 10 2020, 11:54 PM


Group: Member
Posts: 772

It's very interesting to see a lot of famous and high quality luxury packaging exhibitors from Korea and we managed to acquire some prospective suppliers," said Clarabelle Ang, Laboratory Technician with Singapore's Vallaurix Pte Ltd.

https://markets.businessinsider.com/news/st...2019-1028720842
  Forum: By Share Code

odi01
Posted on: Feb 10 2020, 07:30 PM


Group: Member
Posts: 772

https://www.theaustralian.com.au/business/w...f4f1d903380c3d3
  Forum: By Share Code

odi01
Posted on: Feb 10 2020, 02:41 PM


Group: Member
Posts: 772

https://www.morningstar.com.au/stocks/artic...-on-skin/199295
  Forum: By Share Code

odi01
Posted on: Feb 9 2020, 09:23 PM


Group: Member
Posts: 772

https://youtu.be/bG5_tYCvGFo

from 32min 20sec
  Forum: By Share Code

odi01
Posted on: Feb 7 2020, 02:30 AM


Group: Member
Posts: 772

https://finance.yahoo.com/news/eps-growth-t...-234208043.html
  Forum: By Share Code

odi01
Posted on: Feb 6 2020, 06:22 AM


Group: Member
Posts: 772

6 pills everyday

https://www.instagram.com/p/BvpCAuiliZ_/?igshid=hdlsnj74petu
  Forum: By Share Code

odi01
Posted on: Feb 5 2020, 12:45 AM


Group: Member
Posts: 772

https://www.cnbc.com/2020/02/03/cramers-lig...-as-a-spec.html
  Forum: By Share Code

odi01
Posted on: Feb 4 2020, 03:37 AM


Group: Member
Posts: 772

https://www.streetinsider.com/dr/news.php?i...05596&gfv=1
  Forum: By Share Code

odi01
Posted on: Jan 31 2020, 05:43 PM


Group: Member
Posts: 772

https://www.fool.com.au/2020/01/31/avita-me...lf-year-update/
  Forum: By Share Code

odi01
Posted on: Jan 29 2020, 04:53 AM


Group: Member
Posts: 772

https://jabmauisymposium.com/

https://mobile.twitter.com/AvitaMedical/sta...202228900941825
  Forum: By Share Code

odi01
Posted on: Jan 28 2020, 07:25 PM


Group: Member
Posts: 772

https://www.proraris.ch/de/pionierin-bereic...heiten-475.html

When Elisabeth Minder talks about her work at the City Hospital Triemli, she does so with great dedication.
Her commitment has taken her a long way: in 1993, Elisabeth Minder became the first woman to be appointed chief physician at Triemli City Hospital. The medical laboratory institute, which she headed, employed 50 people and had a turnover of 12 million Swiss francs. After training in clinical pharmacology, she first came into contact with porphyria - a group of rare diseases almost all of which are inherited - at the University Hospital of Zurich. Typical of the most well-known form of this disease is an unbearable burning sensation on the skin caused by sunlight. In Switzerland, only about 80 patients suffer from the so-called erythropoietic protoporphyria (EPP).

More and more requests and treatments
At Triemlispital, Elisabeth Minder established the only consultation hour for porphyria patients in Switzerland to date. "That was the condition of my employment. I wanted to combine research with patient care," recalls the former head physician. Her former boss agreed. Since the opening at the beginning of the 1990s, the number of patients has been increasing year by year. Today, about 10 patients per week are received in the porphyria consultation hours - also from abroad. In addition, there are numerous enquiries from professionals and patients who ask the porphyria specialists for advice.

  Forum: By Share Code

odi01
Posted on: Jan 27 2020, 03:56 AM


Group: Member
Posts: 772

https://www.adelaidenow.com.au/subscribe/ne...mp;mode=premium
  Forum: By Share Code

odi01
Posted on: Jan 27 2020, 03:52 AM


Group: Member
Posts: 772

https://youtu.be/wPnoNUbY9DI

go to 1h.10min
  Forum: By Share Code

odi01
Posted on: Jan 26 2020, 02:37 AM


Group: Member
Posts: 772

https://www.azpulse.org/how-the-arizona-bur...-for-burn-care/
  Forum: By Share Code

odi01
Posted on: Jan 23 2020, 01:47 AM


Group: Member
Posts: 772

https://twitter.com/avitamedical/status/121...4968064001?s=21
  Forum: By Share Code

odi01
Posted on: Jan 23 2020, 01:41 AM


Group: Member
Posts: 772

PHILADELPHIA (KYW Newsradio) — Temple University's Burn Center is using new revolutionary biotechnology to treat burn victims. Temple is now using RECELL, a spray-on skin treatment used on burn victims that just approved by the U.S. Food and Drug Administration in January 2019. The treatment is especially helpful to those suffering from large burns. "This enables us to get the patient covered with their own skin more broadly with much less," the center's Lisa Rae said. "In the operating room," she explained, "we take a small piece of their skin, put it in a solution and spray it across the burned area." The treatment limits scaring, but Rae says ultimately, this treatment saves lives because it saves time. "Risk of infection is based on how long your wounds are open. And if we can heal faster we can decrease the overall infection risk," she added. Rae says within 24 hours, the spray-on skin adheres to the wound and begins healing immediately.



https://kywnewsradio.radio.com/articles/new...at-burn-victims
  Forum: By Share Code

odi01
Posted on: Jan 20 2020, 05:22 PM


Group: Member
Posts: 772

https://au.finance.yahoo.com/news/why-think...-055553813.html
  Forum: By Share Code

odi01
Posted on: Jan 20 2020, 01:28 AM


Group: Member
Posts: 772

https://m.facebook.com/story.php?story_fbid...J2Whg8QuxPI0fo4
  Forum: By Share Code

odi01
Posted on: Jan 14 2020, 02:02 PM


Group: Member
Posts: 772

https://www.asx.com.au/asx/statistics/displ...;idsId=02192558
  Forum: By Share Code

odi01
Posted on: Jan 14 2020, 02:02 PM


Group: Member
Posts: 772

https://www.asx.com.au/asx/statistics/displ...;idsId=02192558
  Forum: By Share Code

odi01
Posted on: Jan 14 2020, 02:01 PM


Group: Member
Posts: 772

https://www.fox8live.com/video/2020/01/07/n...mc-burn-center/
  Forum: By Share Code

odi01
Posted on: Jan 11 2020, 07:31 AM


Group: Member
Posts: 772

New Purchase: Avita Medical Ltd (RCEL) Larson Financial Group LLC initiated holding in Avita Medical Ltd. The purchase prices were between $7.1 and $9.7, with an estimated average price of $8.37. The stock is now traded at around $9.30. The impact to a portfolio due to this purchase was 0.02%. The holding were 3,369 shares as of

https://www.gurufocus.com/news/1013383/lars...ercadolibre-inc
  Forum: By Share Code

odi01
Posted on: Jan 10 2020, 03:08 PM


Group: Member
Posts: 772

https://stockhead.com.au/health/health-migh...uccess-in-2020/
  Forum: By Share Code

odi01
Posted on: Jan 10 2020, 03:04 PM


Group: Member
Posts: 772

https://stockhead.com.au/health/health-migh...uccess-in-2020/
  Forum: By Share Code

odi01
Posted on: Jan 10 2020, 02:59 PM


Group: Member
Posts: 772

https://au.finance.yahoo.com/news/2-asx-hea...-024209901.html
  Forum: By Share Code

odi01
Posted on: Jan 10 2020, 02:58 PM


Group: Member
Posts: 772

https://au.finance.yahoo.com/news/2-asx-hea...-024209901.html
  Forum: By Share Code

odi01
Posted on: Jan 10 2020, 02:53 PM


Group: Member
Posts: 772

https://seekingalpha.com/article/4316075-av...e=seeking_alpha.
  Forum: By Share Code

odi01
Posted on: Jan 7 2020, 05:26 PM


Group: Member
Posts: 772

https://www.fool.com/investing/2020/01/06/3...watch-list.aspx
  Forum: By Share Code

odi01
Posted on: Jan 3 2020, 04:56 AM


Group: Member
Posts: 772

https://simplywall.st/stocks/au/pharmaceuti...atchlist-today/
  Forum: By Share Code

odi01
Posted on: Jan 1 2020, 11:42 PM


Group: Member
Posts: 772

https://www.wdsu.com/article/woman-injured-...at-umc/30362386
  Forum: By Share Code

odi01
Posted on: Dec 30 2019, 02:08 PM


Group: Member
Posts: 772

https://au.finance.yahoo.com/news/avita-med...-220147477.html
  Forum: By Share Code

odi01
Posted on: Dec 30 2019, 01:40 PM


Group: Member
Posts: 772

https://www.asx.com.au/asx/statistics/displ...;idsId=02189546
  Forum: By Share Code

odi01
Posted on: Dec 29 2019, 03:14 AM


Group: Member
Posts: 772

https://slatersentinel.com/news/2019/12/27/...is-quarter.html
  Forum: By Share Code

odi01
Posted on: Dec 29 2019, 03:10 AM


Group: Member
Posts: 772

https://newsfilter.io/articles/avita-med-lt...3f1a9c1b5316278


https://finance.yahoo.com/news/biotech-rall...-191907833.html
  Forum: By Share Code

odi01
Posted on: Dec 26 2019, 07:22 PM


Group: Member
Posts: 772

GREENSBORO, N.C. -- A man who survived a plane crash in Boone is sharing his story to inspire others. “I wanted the nurses and doctors to know what he looked liked before the accident,” Judy Worsley said as she held up her iPhone. On the screen, was a photo of her husband John Worsley with sunglasses on, a huge smile and a head full of hair. She doesn’t know when it was taken, “only sometime before the accident.” As she showed the photo, John was sitting next to her on the family couch and staring at the phone. His left eye began to water not for sentimental reasons but because of the damage that was done to it when the plane he was on crashed. His body was severely burned and crushed the moment the plane smashed into a golf course in Boone. At 1:00 p.m. on April 25, John and two of his friends flew from the Boone Airport in a Piper PA-32 aircraft, which, according to an NTSB accident report, belonged to John. In their full report, it is stated that the plane was attempting a maneuver when its wings clipped a pair of pine trees. The plane then crashed into the ground. To this day, John still has not regained parts of his memory from that day in April. Even as he sat down with his family in Greensboro, he scratched his scarred chin and did his best to recall what he could. While John recalled that he was in the pilot's seat, and the plane, according to the NTSB, was registered to him, he has stated that he cannot remember if he was the one operating the aircraft at the time of the crash. “The first thing that I can remember is the smell of smoke. And so I was in the pilot seat and the other two people in the plane were pilots too," John said. Those two people were Benjamin Franklin Chappell, 69, and Steven Cox Berry, 43. Benjamin was killed on impact. John explained that it was a race against the clock for him and Steven to escape the plane that had begun to go up in flames. The flames and heat were beginning to crawl up their backs and spread down their arms and legs. “Steve was in the co-pilots seat and I said, ‘Steve, we’re on fire. We need to get out.’” Steve was stuck and repeatedly told John that he could not get out. John explained that he had to reach out and push open the door, and the two rolled out of the burning metal frame. Witnesses, who described how the plane quickly sped to the ground after clipping the trees, rushed over to the plane to help guide John and Steven away from the flames. The smoke filled the two pilots' eyes, which made it nearly impossible to see. John said he had to crawl on his hands and knees in the direction of where he thought their voices were coming from. The following moments are a blur to the survivor. He said he remembers asking for someone to call his wife, who was six hours away at the beach. He also recalls having a conversation with the EMS crews while he was airlifted to the hospital. Doctors told his wife that because of his age, 68, and the severity of his burns that he would not likely survive. While they did a CT scan that day, they also discovered that John had a tumor on his kidney that could likely impact his chances of making it. “I remember telling the doctors that he wasn’t the typical 68-year-old. We really kind of expected that he’d make it,” Judy said. Determined to help her husband have that fighting chance, Judy pushed for doctors to use an experimental skin regrowth treatment called “RECELL.” John said that “they take a post-it stamp size piece of your skin and they expand it to 70 to 90 times the size of the medium.” That skin is then liquified to the point to where it can be sprayed onto the burn areas in an attempt to replace and recover the damaged area. he spent the next six months in the hospital. During this time, he learned that his friend and co-pilot Steven had passed away from his injuries sustained in the crash. He also had to have his left ankle and leg pinned in place to repair, both of his hands were in casts and his ability to move was limited. With the help of the physicians, his wife and the fuel in his spirit, John walked out of the hospital in October 2016. Three years later, he is still not physically able to do what he once could. He lost his left ear and has to wear hearing aids, he can’t stand in one place for too long with hurting, his hands and fingers aren’t able to close all the way and his skin is no longer able to sweat, meaning he cannot tell when he’s getting too hot. He still has regular therapy and doctor’s visits to replace his skin as needed. However, he decided he would not let those limitations stop him. “I’ve decided that you have one of two choices. You can do whatever it is you can do, or you can sit down and wait to die," John said. He has joined a burn survivor’s group in Winston-Salem and attends the monthly meetings as often as he can. John explained that he wants to share his story to show others their life isn’t over just because the unexpected happened. He recalled a moment from a recent meeting he attended where he sat and listened to victims speak. “They were really angry, they were depressed, and I thought maybe I might be able to help some people," John said. He also said he wants to get behind the controls of a plane again and takes to the skies once more

https://www.google.com/amp/s/myfox8.com/201...olf-course/amp/
  Forum: By Share Code

odi01
Posted on: Dec 24 2019, 03:42 AM


Group: Member
Posts: 772

https://www.instagram.com/p/B6bGIEzlUyk/?ig...d=1kdjfpdmpfxou
  Forum: By Share Code

odi01
Posted on: Dec 23 2019, 12:25 AM


Group: Member
Posts: 772

https://stockhead.com.au/health/dr-borehams...sion-ambitions/
  Forum: By Share Code

odi01
Posted on: Dec 21 2019, 05:18 PM


Group: Member
Posts: 772

https://kalkinemedia.com/2019/12/17/four-po...or-millennials/
  Forum: By Share Code

odi01
Posted on: Dec 21 2019, 05:09 PM


Group: Member
Posts: 772

https://au.finance.yahoo.com/news/were-best...-234810772.html
  Forum: By Share Code

odi01
Posted on: Dec 21 2019, 02:08 PM


Group: Member
Posts: 772

https://6abc.com/health/spray-on-skin-cells...spital/5772622/
  Forum: By Share Code

odi01
Posted on: Dec 21 2019, 02:04 PM


Group: Member
Posts: 772

https://www.templehealth.org/about/news/tem...of-severe-burns
  Forum: By Share Code

odi01
Posted on: Dec 20 2019, 01:09 AM


Group: Member
Posts: 772

https://www.youtube.com/watch?v=3eqGRMwQs8c...amp;app=desktop
  Forum: By Share Code

odi01
Posted on: Dec 19 2019, 05:25 PM


Group: Member
Posts: 772

https://youtu.be/HYvuqTItztc
  Forum: By Share Code

odi01
Posted on: Dec 16 2019, 04:43 AM


Group: Member
Posts: 772

https://thewest.com.au/business/health/red-...-ng-b881411886z
  Forum: By Share Code

odi01
Posted on: Dec 15 2019, 05:48 AM


Group: Member
Posts: 772

https://www.fool.com.au/2019/12/09/3-asx-sh...-value-in-2019/
  Forum: By Share Code

odi01
Posted on: Dec 15 2019, 05:33 AM


Group: Member
Posts: 772

https://www.abc.net.au/news/2019-12-13/how-...lainer/11796426
  Forum: By Share Code

odi01
Posted on: Dec 15 2019, 05:26 AM


Group: Member
Posts: 772

https://kjzz.org/content/1355141/new-zealan...oneered-arizona
  Forum: By Share Code

odi01
Posted on: Dec 13 2019, 07:26 PM


Group: Member
Posts: 772

https://foxbaltimore.com/news/local/new-typ...-park-fire-hero
  Forum: By Share Code

odi01
Posted on: Dec 13 2019, 03:27 PM


Group: Member
Posts: 772

https://www.instagram.com/p/BvpCAuiliZ_/?igshid=hdlsnj74petu


After personal contact to the user "livededfearless", I found out that she had complaints (nausea, tiredness, headaches) after taking MT 7117
  Forum: By Share Code

odi01
Posted on: Dec 13 2019, 03:21 PM


Group: Member
Posts: 772

https://youtu.be/gHRi16VossY
  Forum: By Share Code

odi01
Posted on: Dec 12 2019, 08:07 PM


Group: Member
Posts: 772

Stock letter from Homm

Clinuvel conclusion:
The price of the Clinuvel share has fallen significantly, so that our dusting limits are executed at prices around 26 AUD.
were. In the meantime, the share price has returned to the level before FDA approval. The short attacks, Phillip
Wolgen's compensation package and potential competitors seem to have a greater impact on investors than
they (probably) should.
Clinuvel presented good business figures and its long-term strategy at the Annual General Meeting.
and according to his own statements is in the "endgame". The market for the treatment of UV￾Lichtbedingten DNA damage is enormously promising. In recent years, CUV has developed
extensive experience.
The share trades only approx. 10% above the price target of an extremely one-sided and negative research report of
Moelis Research, Australia, which was published prior to FDA approval. This report has been exclusively
assessed the potential of Scenesse for the treatment of EPP in Europe and the USA at AUD 26.
This study completely ignored the potential of Scenesse for the treatment of EPP in the following markets
in Asia, South America, South Africa, Australia, Canada and New Zealand as well as for other EPP applications.
similar diseases to VP and XP. From our point of view, the XP and VP applications have a
Market potential, which should be significantly higher than for EPP (see Research Summary).
We remain convinced of Clinuvel and have even used the lower prices for acquisitions. We
confirm our price target of AUD 56 (based on the EPP valuation in Europe and the USA). Long-term hold
we offer courses of 150 AUD for possible. Patience and rationality is a virtue in investing.

  Forum: By Share Code

odi01
Posted on: Dec 10 2019, 02:03 PM


Group: Member
Posts: 772

https://kalkinemedia.com/2019/12/09/healthc...-avita-medical/
  Forum: By Share Code

odi01
Posted on: Dec 10 2019, 01:33 AM


Group: Member
Posts: 772

https://investorshub.advfn.com/boards/read_...ge_id=152687139
  Forum: By Share Code

odi01
Posted on: Dec 9 2019, 01:56 PM


Group: Member
Posts: 772

Avita Medical boss Mike Perry says its single-use device is revolutionising care for serious burns patients as the company eyes adjacent areas to use the unique Australian-made technology.The regenerative medicine company's Recell "spray-on skin" product was developed in Perth by Professor Fiona Wood. It aims to address unmet need in therapeutic skin restoration for adults, where patients would traditionally have to receive painful skin grafts.

"The real game-changing element of it is we are returning those melanocytes of pigment-producing cells to the skin, in addition to the skin cells themselves, and we are providing them in an aggregated form," Dr Perry said from his Californian base."We can a take skin for example from the calf of a leg and create a spray-on skin, and spray on someone's face who has second-degree burns. That will come back looking like a face, not like a leg. You are not left with disfiguring scars and from a pain perspective it's huge.

"Dr Perry explained that an adult male would need a skin sample about the size of a credit card to treat a wound on his entire back, rather than skin from both thighs and an arm for a skin graft. Avita has failed to achieve a significant level of market penetration and revenue despite being approved for commercial use outside the US for over a decade. But Dr Perry said that is changing.Avita has been one of the top performers this year on the ASX 200, up over 600 per cent, pushing its market capitalisation to over $1.2 billion despite having just $22.6 million cash, revenue of $7.9 million and no profits.

The company is being rewarded for its low-risk pipeline of new indications, he says, such as the vitiligo – a disease that causes the loss of skin colour in blotches. That market is valued at $US600 million ($877 million) in the US alone, and considered to be the bridge for expansion into the aesthetics space.Avita's next closest opportunity is the outpatient burns setting and treatment of donor sites. It's also looking to pediatrics, scalds and trauma. All up, there is a possible $US2 billion in sales, excluding gene therapy and aesthetics."Vitiligo – we have treated over 1000 patients in China with success and with no failures," Dr Perry said. "We have also had seven publications to support the adoption of Recell for vitiligo."Asia interestAvita is in early talks with possible Chinese partners, while its Japanese partner Cosmotec, owned by Tokyo-listed M3 Group, has submitted its Recell dossier to the authorities for marketing approval.

Avita recently raised $120 million to fund regulatory approvals and randomised clinical trials. It was supported by existing shareholders – Hong Kong's Karst Peak Capital, Redmile Group, and Blackcrane Capital – and by new ones such as Karara Capital and Regal Funds Management.

"Mike Perry has an impressive resume and presents the information well," said Montgomery analyst Joseph Kim. "As investors from Australia we are not always on top of the reimbursement [area]. It's critical."They seem to be on the right path with that, so it's likely why they are getting the take-up with burns units in the US."Dr Perry said he is firmly focused on the US given its size, but declined to give any outlook except to say “we are exceeding our internal targets” and 157 burns doctors out of 300 are trained to use the device in the US.Dr Perry, who took the top job in 2017 after taking early retirement from Novartis, said that using Recell also provides significant cost savings to the health system in reducing the numbers of hospital stays and procedures.

Arizona's Maricopa Integrated Health System estimated it could could save $US28 million a year by using Recell, while a burns centre in Memphis projected to cut costs by up to $US21 million.

Avita also has a powerful ally, US Biomedical Advanced Research and Development Authority, with whom it has long-term funding support. BARDA plans to stockpile its product in case of a burns disaster like a major terrorist attack.

Bell Potter analyst John Hester recently upgraded his call to a buy (speculative) from hold and raised his valuation to 83¢ per share from 69¢. The stock closed Friday at 60¢.He said Recell unit growth in the September quarter was much higher than expected. He is tipping 480 US Recell unit sales in the first quarter of 2020, and 2500 for the full year. The cost per unit is about $7,500.
  Forum: By Share Code

odi01
Posted on: Dec 9 2019, 01:54 PM


Group: Member
Posts: 772

https://www.afr.com/companies/healthcare-an...20191205-p53hbz
  Forum: By Share Code

odi01
Posted on: Dec 8 2019, 09:43 PM


Group: Member
Posts: 772

WASHINGTON, DC – Tacy Gash's whole life changed in five minutes on Memorial Day 2018 when her family home exploded.
Tacy and her husband Bill had just come home from grocery shopping, when they noticed a strong smell of gas.

"I remember the click," said Tacy.
"I remember the whoosh of air cause it was really hot. Strong whoosh of air. And I remember seeing pink."
"When I woke up in the hospital, I had burn marks that came around my face.  It's because the flames came around and clapped my face, then moved on."
The flames burned Tacy on 20% of her body.
Her hands and legs were the worst.   The heat had melted her skin to the carpet.

There are three types of burns:

First-degree burns damage only the outer layer of skin

Second-degree burns damage the outer layer and the layer underneath

Third-degree burns damage or destroy the deepest layer of skin and tissues underneath

During her two weeks in the hospital, doctors recruited Tacy for a clinical trial of ReCell.
It's a kit containing everything a doctor needs to take a small sample of a patient's own skin and turn it into a liquid with the cells needed to regrow new skin.
"Then it gets sucked up into a syringe and then the syringe is outfitted with an atomizer so that you can spray it on," Dr. Jeffrey Shupp, MedStar Washington Burn Center director

Tacy says the areas treated with the spray skin healed *** and the color is better than her burns treated with skin grafted from other areas of her body.
With recell, a piece of healthy skin the size of a postage stamp, can treat a burn 80 times that size.
"It means less donor sites for the patients, which decreases their total wound burden," said Dr. Shupp.
Tacy's husband Bill was not treated with the ReCell because his burns covered 60% of his body and his injuries were too severe.

Bill and Tacy are still recovering from those injuries.
The ReCell kit and spray skin procedure were approved by the FDA.
If this story has impacted your life or prompted you or someone you know to seek or change treatments, please let us know by contacting Jim Mertens at jim.mertens@wqad.com or Marjorie Bekaert Thomas at mthomas@ivanhoe.com.


https://wqad.com/2019/12/06/your-health-spr...ng-on-new-skin/
  Forum: By Share Code

odi01
Posted on: Dec 5 2019, 02:04 PM


Group: Member
Posts: 772

https://www.cnbc.com/video/2019/12/04/avita...n-patients.html
  Forum: By Share Code

odi01
Posted on: Dec 2 2019, 04:58 AM


Group: Member
Posts: 772

The Patient Perspective: A Matter of Minutes
Swiss Society for Porphyria - www.porphyria.ch
1. DEZ. 2019 —

The Patient, the scientific journal dedicated to patient-centered outcomes research, has published a commentary authored by Rocco Falchetto, describing how patient input can contribute to medical product research and development processes, regulatory reviews, health technology assessments and reimbursement decision making. The article builds directly from Falchetto’s presentation in the symposium, “Patient preferences in the medical treatment lifecycle” at the 10th Meeting of the International Academy of Health Preference Research (IAHPR) in Basel, Switzerland, on the 13th of July 2019. It focuses on the arduous years-long patient journey to access afamelanotide, illustrates challenges and opportunities in the inclusion of the patient voice in the lifecylce of medicines, and calls for a stronger integration of the patient perspective in health systems’ decision-making processes.

We look forward to the article contributing to raising awareness on the urgent need for a full integration of the perspective of patients in decisions affecting their health and well-being as well as to a better understanding of EPP and the benefits of afamelanotide. As Falchetto concludes in his article, we hope that skeptical decision makers will reconsider their views on the value of this life-changing treatment, giving those who suffer from EPP a second chance to finally step out from the shadows and into life as fully productive and engaged members of society.

https://www.change.org/p/ein-leben-ohne-son...amp;utm_term=cs
  Forum: By Share Code

odi01
Posted on: Dec 2 2019, 12:17 AM


Group: Member
Posts: 772

https://dfscaller.com/avita-med-ltd-s-nasda...tment-research/
  Forum: By Share Code

odi01
Posted on: Dec 2 2019, 12:14 AM


Group: Member
Posts: 772

https://kalkinemedia.com/2019/12/01/whats-l...sb-avh-cuv-reg/
  Forum: By Share Code

odi01
Posted on: Dec 2 2019, 12:13 AM


Group: Member
Posts: 772

https://kalkinemedia.com/2019/12/01/whats-l...sb-avh-cuv-reg/
  Forum: By Share Code

odi01
Posted on: Nov 29 2019, 05:37 PM


Group: Member
Posts: 772

https://au.finance.yahoo.com/news/why-avita...-034017662.html
  Forum: By Share Code

odi01
Posted on: Nov 26 2019, 07:40 PM


Group: Member
Posts: 772

Changes in index house MSCI's country indexes has sparked some heavy trading at the close on Tuesday. . . .

The MSCI Australia Index is designed to measure the performance of Australia's large and mid cap segments and has about 70 members.There was also some unusual trading at the smaller end of the market to reflect changes to the MSCI Australia Small Cap Index.MSCI's additions included Austal, Avita Medical, Bank of Queensland, Centuria Metropolitan REIT, Ecofibre, EML Payments, IMF Bentham, Ingenia, iSignthis, Perseus Mining, Polynovo and Ramelius Resources. Deletions included OFX Group, Speedcast, Syrah, Wagners and WiseTech."
  Forum: By Share Code

odi01
Posted on: Nov 26 2019, 06:42 PM


Group: Member
Posts: 772

https://www.afr.com/street-talk/msci-change...20191126-p53ec5
  Forum: By Share Code

odi01
Posted on: Nov 25 2019, 07:43 PM


Group: Member
Posts: 772

https://au.finance.yahoo.com/news/avita-med...-002521079.html
  Forum: By Share Code

odi01
Posted on: Nov 25 2019, 06:58 PM


Group: Member
Posts: 772

https://www.asx.com.au/asx/statistics/displ...;idsId=02176774

https://www.asx.com.au/asx/statistics/displ...;idsId=02177248

https://www.asx.com.au/asx/statistics/displ...;idsId=02177116



  Forum: By Share Code

odi01
Posted on: Nov 20 2019, 01:56 AM


Group: Member
Posts: 772

https://www.wndu.com/content/news/Spray-on-...-564936092.html
  Forum: By Share Code

odi01
Posted on: Nov 18 2019, 09:05 PM


Group: Member
Posts: 772

https://www.nytimes.com/reuters/2019/11/18/...bishi-chem.html
  Forum: By Share Code

odi01
Posted on: Nov 14 2019, 06:09 AM


Group: Member
Posts: 772

https://www.actasanitaria.com/posicionamien...a-y-eculizumab/


https://www.actasanitaria.com/wp-content/up...a-Intrarosa.pdf
  Forum: By Share Code

odi01
Posted on: Nov 12 2019, 03:28 PM


Group: Member
Posts: 772

https://simplywall.st/stocks/au/pharmaceuti...are-price-gain/
  Forum: By Share Code

odi01
Posted on: Nov 12 2019, 03:25 PM


Group: Member
Posts: 772

https://hotcopper.com.au/threads/powerful-c...ost_id=41379894
  Forum: By Share Code

odi01
Posted on: Nov 11 2019, 09:36 PM


Group: Member
Posts: 772

https://www.afr.com/street-talk/avita-medic...20191111-p539e7
  Forum: By Share Code

odi01
Posted on: Nov 11 2019, 03:40 PM


Group: Member
Posts: 772

https://hotcopper.com.au/documentdownload?i...eFxke92GA%3D%3D
  Forum: By Share Code

odi01
Posted on: Nov 10 2019, 05:24 PM


Group: Member
Posts: 772

https://kalkinemedia.com/2019/11/10/lens-ov...eturns-avh-pnv/
  Forum: By Share Code

odi01
Posted on: Nov 10 2019, 05:10 PM


Group: Member
Posts: 772

https://www.volkskrant.nl/de-gids/voor-mens...w.google.com%2F
  Forum: By Share Code

odi01
Posted on: Nov 10 2019, 05:04 PM


Group: Member
Posts: 772

https://www.demorgen.be/leven-liefde/altijd...w.google.com%2F
  Forum: By Share Code

odi01
Posted on: Nov 9 2019, 05:19 PM


Group: Member
Posts: 772

Another new addition is the Australian company Clinuvel Pharmaceuticals. The pharmaceutical manufacturer specializes in the treatment of rare diseases. In October, the US approval of the drug for the treatment of the light intolerance disease EPP was celebrated. Further approvals are in the pipeline, so we expect the positive development to continue.

https://www.fondsdiscount.de/magazin/news/t...nt-in-den-4404/
  Forum: By Share Code

odi01
Posted on: Nov 8 2019, 07:46 PM


Group: Member
Posts: 772

https://www.fool.com.au/2019/11/08/avita-me...to-the-asx-200/
  Forum: By Share Code

odi01
Posted on: Nov 8 2019, 07:43 PM


Group: Member
Posts: 772

https://www.wmcactionnews5.com/2019/11/04/s...fts-some-burns/
  Forum: By Share Code

odi01
Posted on: Nov 8 2019, 03:46 PM


Group: Member
Posts: 772

https://www.asx.com.au/asx/statistics/displ...;idsId=02170626
  Forum: By Share Code

odi01
Posted on: Nov 8 2019, 12:03 AM


Group: Member
Posts: 772

https://www.morningstar.com.au/Stocks/Signa...20191107/474754
  Forum: By Share Code

odi01
Posted on: Nov 7 2019, 06:29 PM


Group: Member
Posts: 772

https://www.afr.com/companies/healthcare-an...20191107-p5388n
  Forum: By Share Code

odi01
Posted on: Nov 6 2019, 03:17 AM


Group: Member
Posts: 772

https://www.msn.com/en-us/news/videos/crame...ckRedirect=true

0,44 min
  Forum: By Share Code

odi01
Posted on: Nov 5 2019, 05:10 PM


Group: Member
Posts: 772

https://www.livewiremarkets.com/wires/is-th...r-avita-medical
  Forum: By Share Code

odi01
Posted on: Nov 4 2019, 01:51 PM


Group: Member
Posts: 772

https://au.finance.yahoo.com/news/why-avita...-225230745.html
  Forum: By Share Code

odi01
Posted on: Nov 4 2019, 01:50 PM


Group: Member
Posts: 772

https://www.nbcdfw.com/news/local/Spray-On-...-564244341.html
  Forum: By Share Code

odi01
Posted on: Nov 1 2019, 07:42 PM


Group: Member
Posts: 772

https://rogermontgomery.com/is-there-more-u...-avita-medical/
  Forum: By Share Code

odi01
Posted on: Nov 1 2019, 07:39 PM


Group: Member
Posts: 772

https://www.marketbeat.com/stocks/NASDAQ/RCEL/price-target/
  Forum: By Share Code

odi01
Posted on: Oct 31 2019, 05:28 PM


Group: Member
Posts: 772

https://www.fool.com.au/2019/10/31/clinuvel...arterly-update/
  Forum: By Share Code

odi01
Posted on: Oct 30 2019, 04:09 PM


Group: Member
Posts: 772

https://www.nice.org.uk/guidance/mtg21
  Forum: By Share Code

odi01
Posted on: Oct 29 2019, 05:08 PM


Group: Member
Posts: 772

https://www.mpo-mag.com/contents/view_break...-recell-system/
  Forum: By Share Code

odi01
Posted on: Oct 25 2019, 04:48 PM


Group: Member
Posts: 772

https://simplywall.st/stocks/au/pharmaceuti...26-undervalued/
  Forum: By Share Code

odi01
Posted on: Oct 18 2019, 10:22 AM


Group: Member
Posts: 772

http://finance.eastmoney.com/a/201910181264595557.html
  Forum: By Share Code

odi01
Posted on: Oct 15 2019, 10:03 PM


Group: Member
Posts: 772

https://trends.google.com/trends/explore?da...&q=Clinuvel
  Forum: By Share Code

odi01
Posted on: Oct 10 2019, 08:21 PM


Group: Member
Posts: 772

http://www.more-ir.de/d/19163.pdf
  Forum: By Share Code

odi01
Posted on: Oct 10 2019, 08:10 PM


Group: Member
Posts: 772

https://www.asx.com.au/asx/statistics/displ...;idsId=02157537
  Forum: By Share Code

odi01
Posted on: Oct 10 2019, 10:34 AM


Group: Member
Posts: 772

https://www.reuters.com/article/clinuvel-ph...s-idUSL3N26U4BZ
  Forum: By Share Code

odi01
Posted on: Oct 9 2019, 09:49 PM


Group: Member
Posts: 772

https://www.thelantern.com/2019/09/wexner-m...to-treat-burns/
  Forum: By Share Code

odi01
Posted on: Oct 9 2019, 09:46 PM


Group: Member
Posts: 772

https://www.youtube.com/watch?v=sWettU9CYLk
  Forum: By Share Code

odi01
Posted on: Oct 9 2019, 11:15 AM


Group: Member
Posts: 772

Attached Image

  Forum: By Share Code

odi01
Posted on: Oct 9 2019, 11:14 AM


Group: Member
Posts: 772

Attached Image

  Forum: By Share Code

odi01
Posted on: Oct 9 2019, 11:13 AM


Group: Member
Posts: 772

Attached Image

  Forum: By Share Code

odi01
Posted on: Oct 9 2019, 09:58 AM


Group: Member
Posts: 772

https://youtu.be/XpO0ROiNRys
  Forum: By Share Code

odi01
Posted on: Oct 9 2019, 09:11 AM


Group: Member
Posts: 772

https://m.facebook.com/AmericanPorphyriaFou...gins%2Fpage.php
  Forum: By Share Code

odi01
Posted on: Oct 8 2019, 11:02 AM


Group: Member
Posts: 772

https://www.fondsdiscount.de/magazin/news/i...mber-2019-4320/



We have also included Clinuvel Pharmaceuticals Ltd. in our portfolio. The company specializes in skin diseases caused by genetic defects. The drug Scenesse is the only product in Europe that is used to treat EPP. The therapy enables patients to live in the light again, which was previously impossible or only possible under severe pain. In the USA, the health authorities are currently deciding on the approval there.

  Forum: By Share Code

odi01
Posted on: Oct 8 2019, 10:53 AM


Group: Member
Posts: 772

https://simplywall.st/stocks/au/pharmaceuti...limited-asxcuv/
  Forum: By Share Code

odi01
Posted on: Oct 8 2019, 07:51 AM


Group: Member
Posts: 772

https://finance.yahoo.com/news/imagine-elat...-200457259.html
  Forum: By Share Code

odi01
Posted on: Oct 7 2019, 06:54 PM


Group: Member
Posts: 772

https://au.finance.yahoo.com/news/clinuvel-...-021545876.html
  Forum: By Share Code

odi01
Posted on: Oct 6 2019, 08:19 PM


Group: Member
Posts: 772

https://www.yourcentralvalley.com/video/med...iently/3990008/
  Forum: By Share Code

odi01
Posted on: Oct 2 2019, 01:53 PM


Group: Member
Posts: 772

3:30 – 4:00
pm
Burn Care Without Borders
Judy L. Placek, MSN, APRN Karen L. Winn, MSN, ACNP, RN
Nurse Practitioner, Plastic & Burn Surgery Manager, Medical Education
Nebraska Medicine, Omaha, NE Avita Medical, Valencia, CA

https://midwestregionburn.centerforconferences.uiowa.edu/
  Forum: By Share Code

odi01
Posted on: Oct 1 2019, 12:45 AM


Group: Member
Posts: 772

https://www.businesswire.com/news/home/2019...-Listing-Nasdaq
  Forum: By Share Code

odi01
Posted on: Sep 30 2019, 01:07 PM


Group: Member
Posts: 772

https://www.asx.com.au/asx/statistics/displ...;idsId=02152872
  Forum: By Share Code

odi01
Posted on: Sep 27 2019, 01:42 PM


Group: Member
Posts: 772

https://www.asx.com.au/asx/statistics/displ...;idsId=02152098
  Forum: By Share Code

odi01
Posted on: Sep 25 2019, 11:30 PM


Group: Member
Posts: 772

http://archive.fast-edgar.com//20190925/A7...XOCOHKEZ22Z2B2/
  Forum: By Share Code

odi01
Posted on: Sep 24 2019, 10:28 PM


Group: Member
Posts: 772

https://www.raskmedia.com.au/2019/09/24/cli...rd-appointment/
  Forum: By Share Code

odi01
Posted on: Sep 24 2019, 06:48 PM


Group: Member
Posts: 772

https://sec.report/Document/0001193125-19-249606/
  Forum: By Share Code

odi01
Posted on: Sep 24 2019, 06:42 PM


Group: Member
Posts: 772

https://seekingalpha.com/article/4293086-st...-play-revisited
  Forum: By Share Code

odi01
Posted on: Sep 20 2019, 12:23 AM


Group: Member
Posts: 772

https://thefly.com/landingPageNews.php?id=2...-meet-with-BTIG
  Forum: By Share Code

odi01
Posted on: Sep 20 2019, 12:15 AM


Group: Member
Posts: 772

https://thefly.com/permalinks/entry.php/id2...-at-Lake-Street
  Forum: By Share Code

odi01
Posted on: Sep 19 2019, 01:54 PM


Group: Member
Posts: 772

https://www.asx.com.au/asx/statistics/displ...;idsId=02148645
  Forum: By Share Code

odi01
Posted on: Sep 19 2019, 04:53 AM


Group: Member
Posts: 772

https://www.fool.com.au/2019/09/18/why-the-...nd-625-in-2019/
  Forum: By Share Code

odi01
Posted on: Sep 18 2019, 11:18 PM


Group: Member
Posts: 772

Three hours of sun - New studies on EPP under treatment!

Jasmine Barman Aksözene
Mannheim, AL, Germany


17TH SEP. 2019 —

Normally, EPP patients experience the first symptoms such as burning and pain within a few minutes in the sun. When treated with afamelanotide, they can lead an almost completely normal life and spend hours outdoors.

How long exactly has now been recorded in two studies with patients from Switzerland, the Netherlands and the USA, which were presented at the International Congress on Porphyria, 8-11 September in Milan: In the Swiss study, the tolerance for phototoxic reactions increased from a median of 10 minutes to a median of 180 minutes. In the Netherlands and USA, where a different protocol was used to record time, many patients claimed to be able to spend more than 360 minutes outdoors without symptoms.

These results finally reflect the patients' experience! Instead of calculating mean values as in previous studies, where rainy days and time spent in the office of course massively dilute the measured effect, the treatment centres now document what is relevant for us patients: How long can I actually stay outside on sunny days without suffering massive burns and pain - if I have the time and the sun is shining. Both manuscripts are in preparation for submission to scientific journals.

This adaptation in the measuring procedure represents an important step in learning how to measure the effect of treatment with EPP - since there has never been an effective therapy for EPP before, the first studies did not know exactly how best to measure the effect of afamelanotide. This makes it all the more important to listen to the patients and their caregivers in rare diseases, because they know best whether a treatment will benefit them or not. We hope that the European Medicines Agency and the FDA finally understand and acknowledge the benefits of treatment for us patients on the basis of these data and change their unscientific conclusions, which currently make access to treatment considerably more difficult. It is unacceptable that patients should not have access to the only and demonstrably highly effective treatment for their disease, or that they should fear that this new life will be taken away from them in the light and without burns.

Photo: International Porphyria Patient Network (IPPN) in front of the posters on the successful appeal procedure in England and the poster on acute hepatic porphyria in science slam style.

https://www.change.org/p/licht-f%C3%BCr-all...amp;utm_term=cs
  Forum: By Share Code

odi01
Posted on: Sep 17 2019, 02:04 PM


Group: Member
Posts: 772

https://www.asx.com.au/asx/statistics/displ...;idsId=02147635
  Forum: By Share Code

odi01
Posted on: Sep 12 2019, 10:03 PM


Group: Member
Posts: 772

https://finance.yahoo.com/news/avita-medica...k0CtNi4jsVMQXfl
  Forum: By Share Code

odi01
Posted on: Sep 11 2019, 04:09 AM


Group: Member
Posts: 772

https://www.thelantern.com/2019/09/wexner-m...to-treat-burns/
  Forum: By Share Code

odi01
Posted on: Sep 11 2019, 04:04 AM


Group: Member
Posts: 772

RENDING
PORTFOLIO
PEOPLE
MARKET NEWS
STOCK IDEAS
DIVIDENDS
INVESTING STRATEGY
REITS
WALL STREET BREAKFAST
ON THE MOVE
DIVIDEND NEWS
MARKET OUTLOOK
Overlooked and Underfollowed profile picture.
Overlooked and Underfollowed
Long Ideas
Healthcare
Stereotaxis - Acquisition Of Robotic Vascular Peer Underscores Substantial Upside Potential, Private Placement Another Positive
Sept. 3, 2019 2:05 PM ETStereotaxis, Inc. (STXS)AVMXY, CVRS, ISRG...13 Comments
Summary
Active M&A environment in Robotic Medical Device Segment continues with Siemens Healthineers’ $1.1 billion acquisition of Stereotaxis’ peer Corindus Vascular Robotics.
CVRS acquisition validates significant market potential for robotics in cardiac and neurovascular markets, and the P/S multiples paid for it would imply a $13-26/share valuation for STXS.
As per the latest of 350+ peer-reviewed publications, Stereotaxis robotic platform now carries trifecta of clinical superiority, safety and speed.
Securing $25 million via private placement from smart healthcare funds, including Redmile Group, provides foundation for faster growth and expansion of procedure indications.
Stereotaxis recently discussed opportunity to target cancer for first time, and that's noteworthy on heels of J&J's $5 billion Auris Health acquisition.
Active M&A Environment in Robotic Medical Device Segment Continues; Following J&J’s Acquisition of Auris Health for $5 Billion in February 2019, Stereotaxis’ Robotic Vascular Peer Corindus Vascular Robotics (NYSEMKT:CVRS) is being Acquired for $1.1 Billion by Siemens Healthineers; Notably Stereotaxis has Similar (if not Larger) Growth Opportunity Ahead

In the valuation/summary section of the prior SA article posted in May 2019 entitled Stereotaxis: Well Positioned To Become 'Intuitive Surgical Of Endovascular Surgery' With Genesis Launch And Proprietary Catheter Development, Corindus Vascular Robotics was highlighted as one of two robotic medical peers trading at a significantly higher P/Sales multiple than Stereotaxis (OTC:STXS). Since that analysis, Siemens Healthineers (OTCPK:SMMNY) has bid $1.1 billion to acquire Corindus, making Stereotaxis’ current valuation even more attractive, especially considering their higher revenues, lower cash burn, nearness to profitability, larger install base, and similar (if not greater) growth opportunity ahead.


Placing comparable P/S multiples on Stereotaxis for what Corindus was acquired for (102x, ~61X, and ~38X on actual FY18, estimated FY19, and estimated FY20 revenues respectively) would yield a value between $13-26/share for STXS today. This valuation range takes into consideration Stereotaxis’ higher shares outstanding, now approximately 114 million shares after the recent $25 million private placement led by Redmile Group.

Clearly these valuation levels reflect a takeout price of a robotic vascular peer, and this section is not suggesting that Stereotaxis is worth those levels today based on its fundamentals. Yet the future growth opportunity is arguably just as large, if not larger, for Stereotaxis as it is for Corindus as well as for Auris Health, which was acquired by J&J (JNJ) for $5 billion in February 2019.

As discussed in the prior SA article, Stereotaxis has broad regulatory clearance across the vascular system, including neurovascular, peripheral anatomy, and coronary vasculature procedures, making its total addressable market quite significant. Its unique robotic "pull" mechanism of action utilizes magnetism to more precisely and safely steer devices throughout the vascular system, as opposed to other robotic and manual approaches that use a “push” mechanism of action. This magnetic “pull” approach allows reach into areas of the vascular system that would be otherwise inaccessible via “push” approaches, including robotic and manual.

In light of this significant market opportunity and superior approach, under an acquisition scenario I do believe Stereotaxis can garner a value closer to $13-16/share based on similar forward P/sales metrics for FY2019 & FY2020 that Corindus is receiving at the $1.1 billion price tag, or even higher when taking into consideration the $5 billion ($3.4 billion in cash upfront) J&J paid for Auris Health earlier this year. This ‘takeout’ valuation level for STXS conservatively assumes $29 million in FY2019 sales growing to $38 million in FY2020, representing 31% year-over-year growth. Beyond 2020, Stereotaxis should see continued rapid growth for multiple years driven by new/replacement sales of its Genesis system along with the launch of its proprietary catheter currently under development. On its recent Q2’2019 conference call, CEO David Fischel noted that since unveiling their Innovation Plan three months ago it has been“an amazingly energetic period…The broad enthusiastic response validates that our innovation and strategic decisions were sound…We are confident in our expectation for significant revenue growth in the years ahead”.


Source: http://www.roboticep.com

Here is some more detail on the revenue estimates provided for FY2019, FY2020, and beyond:

For FY2019 - The $29 million estimate is based on ~$28 million in recurring high-margin revenue plus one new Niobe system sale to the Kansas City Heart Rhythm Institute to treat arrhythmia patients, which will be recognized in fiscal Q3’2019. This updated estimate for FY2019 factors in the receipt of a CE Mark for its Genesis system in May 2019 and a 6+ month sales cycle. On the Q2 call the CEO provided the following detail on Europe, US, Q3 outlook and color around new/replacement Genesis cycle: “In Europe, where we have regulatory clearance for the full robotic lab solution, including Genesis and Stereotaxis Imaging, we've begun engaging with existing hospital customers on replacement projects and with new potential customers on building robotic EP labs. In the US, we are advancing towards regulatory approval...In the third quarter, we expect to recognize the sale of a new Niobe robotic system to Overland Park Regional Medical Center, part of HCA Midwest Health. We expect in the coming months to be able to provide you with additional confidence that the replacement cycle opportunity for Genesis is real, and that our innovations support robotic adoption by new customers”.
For FY2020 - The $38 million estimate suggests growth of 31% y-o-y and represents the beginning of a multi-year replacement cycle for the Genesis system, with contributions from both Europe (CE Mark received in May 2019) and the US (pending FDA approval of the system which I anticipate within the next 4-6 months). As previously detailed in the prior SA article, management sees potential for ~$15 million annually from a Genesis replacement cycle. Considering (1) a 6+ month sales cycle, (2) CE Mark approval in May 2019, and (3) expected FDA approval near year-end, the $38 million revenue estimate for FY2020 factors the company achieving $9 million in replacement and new Genesis system sales. With respect to potential timing of FDA approval and a full global launch, management stated on the Q2 call: “We still think that some timeline around the end of this year, beginning of next year as a full launch globally seems reasonable”.
Beyond FY2020 - While this analysis will not look past 2020 in terms of specific revenue estimates, moving into FY2021 and beyond I’d anticipate the Genesis replacement cycle will be closer to management’s $15 million annual estimate. Stereotaxis’ other major driver of future sales is their proprietary catheter currently under development in collaboration with Osypka. As discussed in the prior SA article, management estimated that using just their existing global procedure volume its proprietary ablation catheter could generate "over $20 million in incremental high-margin annual revenue". That suggests potentially ~$48 million in high-margin recurring revenues annually after the launch of the catheter, without adding a single new customer. From a timeline perspective, management anticipates potential European approval for its proprietary catheters by the end of 2020 and potential FDA approval by 2022/2023, based off their comments on their Q1'2019 call.

From an overall profit perspective, the $38 million sales estimate for FY2020 could lead to a similar profit margin near the 72% achieved in FY2015; that is the last year the company had $10 million in hardware sales (generated from Niobe and Odyssey system sales). Given the costs that have been removed from the model in recent years, that could mean Stereotaxis reaching profitability next year just on the Genesis replacement cycle alone. Additionally, based on management commentary we may see some proprietary catheter sales beginning in 2H of 2020 in their sizeable European market, that would be additive to any replacement or new Genesis system sales. The sooner-than-later accretive nature of Stereotaxis should bolster its potential as a takeover candidate…more on that potential later.

Stereotaxis Robotic System has Regulatory Clearance for Navigation of Interventional Devices Broadly Throughout Vascular System; Recent $25 Million Private Placement Led by Redmile Group Will Help Speed Up Innovation in Electrophysiology and Kickstart Novel Applications Beyond Cardiac Ablation; Attracting Healthcare-Focused Institutional Investor Like Redmile Group is a Positive Development

From an expansion of procedures perspective, Stereotaxis has remained prudently focused on its large opportunity in cardiac ablation procedures, yet it has broad regulatory clearance throughout the vascular system, including cardiac, neurovascular and peripheral vascular procedures. Management has referred to the Genesis robotic system as a launching pad for future expansion noting "it serves as a platform on which potential future ventures in new endovascular anatomies are possible" and it is “a platform able to accommodate significant innovation in the future".

As mentioned, the total addressable market between cardiac, neurovascular, and peripheral procedures is quite significant. Stereotaxis has been cash constrained for years limiting its focus to cardiac ablation procedures, but thanks to a management/Board-led investment of $34 million in recent years and a new $25 million private placement in August 2019, that is changing for the better creating a substantial opportunity ahead for current and future shareholders. When discussing that $25 million private placement led by Redmile Group LLC on the Q2 call, the CEO had the following comments on broadening applications beyond cardiac ablation and expanding the sales team to better capture Stereotaxis’ significant opportunity ahead:

“This financing will allow us to initiate earlier, and advance more rapidly, multiple undisclosed innovation projects. I classify these projects into two general categories: a second wave of innovation in electrophysiology and novel applications for robotic magnetic navigation in interventional medicine. These projects will not have near-term impact on revenue, but are expected to have highly attractive IRRs to fuel future market share growth in electrophysiology and to create additional pillars of value for Stereotaxis outside of electrophysiology. I look forward to sharing additional updates as appropriate..."
"…A strong balance sheet will accelerate and support our commercial growth activities…While I'm confident the existing teams will be able to successfully commercialize our Genesis robotic system and next-generation ablation catheter at existing customers, we have limited bandwidth to focus on the 99% of the electrophysiology market that is not currently robotic. There's a real opportunity is that Stereotaxis has less than 1% share of a $4 billion and growing market. Given the clinical benefits of our technology, every electrophysiology lab should have a robotic system. This financing will allow us to thoughtfully expand our global commercial teams and execute on the opportunity.”
Management commentary on recent quarterly calls highlight that future expansion beyond cardiac is now clearly in focus for Stereotaxis, and their intent to expand procedure indications is more evident today than it has been since the company originally went public. The prior SA article discussed potential expansion into neurovascular applications (in particular for stroke patients), peripheral anatomy, pulmonary indications, and bronchial anatomy. Another indication has come to light since that last SA article was published in May 2019…cancer.


While the July 2019 article in Robotics Tomorrow entitled “Treating Heart Disease with Robotic Precision and Safety” did not have much new info, it was the first time I've ever seen cancer specifically mentioned as an area of potential focus. When asked "What type of patients does it impact now and who might it help in the future?”, Stereotaxis CEO answered: “Stereotaxis RMN is currently used to help treat patients suffering from cardiac arrhythmias... arrhythmias affect tens of millions of individuals worldwide. The technology serves as a platform for performing minimally invasive endovascular procedures. Looking ahead, Stereotaxis intends to apply the benefits of its robotic technology and proven safety into other fields, such as in the treatment of stroke, vascular disease, and various cancers." As mentioned in the prior SA article, the $5+ billion acquisition of Auris Health by J&J carries implications for Stereotaxis, and notably Auris' initial focus is on lung cancer...more on that later.

Shifting back to Redmile Group LLC, it is a ~$3 billion fund known for their healthcare focus and expertise that according to Bloomberg has 97% of its portfolio invested in healthcare. Having them lead the $25 million private placement is a major win for Stereotaxis and represents an inflection point in the management/Board led turnaround effort. With respect to my own experience with Redmile Group, I’ve had the good fortune of being involved in another medical device name that they also led a private placement in. That company is Avita Medical (OTCQX:AVMXY, AVH.AU), and from a 10,000-foot level there are broad similarities between the two companies including:

both have promising technologies that under prior management had not reached their full potential,
both have next generation platforms that could be transformational to their respective markets,
both are in a situation where a large capital infusion can help advance “idle-waiting-to-be-kickstarted” applications & pipeline opportunities into additional high-value areas, and
both have a clear edge from a clinical perspective, including efficacy and safety, over current ‘standard-of-care’ conventional approaches.
Let’s hope there is one other similarity here; Avita Medical shares have appreciated roughly 500% in the 9 months since its private placement that Redmile Group led in December 2018. I believe Stereotaxis has similar potential over the next 12-18 months, and it is reassuring to see smart institutional money like Redmile invest in the company at these levels and at this juncture.

https://seekingalpha.com/article/4289369-st...pside-potential

  Forum: By Share Code

odi01
Posted on: Sep 10 2019, 08:14 PM


Group: Member
Posts: 772

https://finfeed.com/small-caps/biotech/heal...-sector-part-1/
  Forum: By Share Code

odi01
Posted on: Sep 7 2019, 04:25 AM


Group: Member
Posts: 772

https://vimeo.com/344750025

Sorry
  Forum: By Share Code

odi01
Posted on: Sep 7 2019, 04:22 AM


Group: Member
Posts: 772

https://vimeo.com/357821778
  Forum: By Share Code

odi01
Posted on: Sep 6 2019, 01:30 PM


Group: Member
Posts: 772

https://www.finnewsnetwork.com.au/archives/...work263896.html
  Forum: By Share Code

odi01
Posted on: Sep 6 2019, 11:40 AM


Group: Member
Posts: 772

https://www.asx.com.au/asx/statistics/displ...;idsId=02144031
  Forum: By Share Code

odi01
Posted on: Sep 5 2019, 10:08 PM


Group: Member
Posts: 772

https://www.sciencedirect.com/science/artic...305417918308830
  Forum: By Share Code

odi01
Posted on: Sep 4 2019, 01:40 PM


Group: Member
Posts: 772

https://www.fool.com.au/2019/09/04/why-brav...ed-lower-today/
  Forum: By Share Code

odi01
Posted on: Sep 3 2019, 02:34 AM


Group: Member
Posts: 772

https://hotcopper.com.au/threads/par-v-cuv....ost_id=40282980
  Forum: By Share Code

odi01
Posted on: Aug 30 2019, 10:46 PM


Group: Member
Posts: 772

https://www.livewiremarkets.com/wires/a-loo...ed-to-tailwinds
  Forum: By Share Code

odi01
Posted on: Aug 30 2019, 03:58 AM


Group: Member
Posts: 772

https://onlinelibrary.wiley.com/doi/full/10.1111/pcmr.12802
  Forum: By Share Code

odi01
Posted on: Aug 28 2019, 09:28 PM


Group: Member
Posts: 772

https://www.instagram.com/p/B1tEogChL5t/
  Forum: By Share Code

odi01
Posted on: Aug 28 2019, 01:50 PM


Group: Member
Posts: 772

https://kalkinemedia.com/2019/08/28/clinuve...-revenue-up-22/
  Forum: By Share Code

odi01
Posted on: Aug 25 2019, 06:32 PM


Group: Member
Posts: 772

https://westfaironline.com/115630/bridgepor...r-burn-victims/
  Forum: By Share Code

odi01
Posted on: Aug 23 2019, 03:19 PM


Group: Member
Posts: 772

https://www.asx.com.au/asx/statistics/displ...;idsId=02137474
  Forum: By Share Code

odi01
Posted on: Aug 17 2019, 01:31 PM


Group: Member
Posts: 772

https://abc6onyourside.com/news/local/spray...-wound-patients
  Forum: By Share Code

odi01
Posted on: Aug 13 2019, 01:10 AM


Group: Member
Posts: 772

https://www.sciencedirect.com/science/artic...305417918308830
  Forum: By Share Code

odi01
Posted on: Aug 9 2019, 10:43 PM


Group: Member
Posts: 772

https://journals.sagepub.com/doi/full/10.11...399202619865167
  Forum: By Share Code

odi01
Posted on: Aug 7 2019, 03:15 PM


Group: Member
Posts: 772

https://www.fool.com.au/2019/08/07/is-the-c...n-the-buy-zone/
  Forum: By Share Code

odi01
Posted on: Aug 2 2019, 01:53 PM


Group: Member
Posts: 772

https://spotonohio.com/central-ohio/631204/...ner-center.html
  Forum: By Share Code

odi01
Posted on: Aug 2 2019, 01:44 AM


Group: Member
Posts: 772

https://backend.otcmarkets.com/otcapi/compa...r/report/AVMXY/
  Forum: By Share Code

odi01
Posted on: Jul 31 2019, 04:50 PM


Group: Member
Posts: 772

https://seekingalpha.com/article/4279341-ho...neration-device
  Forum: By Share Code

odi01
Posted on: Jul 31 2019, 12:51 PM


Group: Member
Posts: 772

https://www.avitamedical.com/uploads/pdf/AV...019-Final32.pdf
  Forum: By Share Code

odi01
Posted on: Jul 31 2019, 02:03 AM


Group: Member
Posts: 772

https://www.gesundheitsstadt-berlin.de/wenn...rankheit-13366/

The active ingredient is administered in the form of a small capsule which is placed under the skin and dissolves there for two months. "This treatment must be carried out every two months, preferably throughout the year," describes Stephan Grabbe
  Forum: By Share Code

odi01
Posted on: Jul 29 2019, 03:00 PM


Group: Member
Posts: 772

https://www.ctpost.com/local/article/Bridge...ts-14188634.php
  Forum: By Share Code

odi01
Posted on: Jul 24 2019, 07:11 PM


Group: Member
Posts: 772

Und dann
endlich, nach all der Leidenszeit,
bekam sie eine Therapie, die wirk-
lich half. Ein riesiges Glück, denn
derzeit können längst nicht alle
Betroffenen behandelt werden.
„Am 26. Juni 2017, das weiß ich
noch genau, bekam ich das erste
Scenesse-Implantat“, erzählt sie.
Und das Medikament wirkte. Doch
die Angst vor den Schmerzen blieb
– erst mal. „Ich habe mich ein Jahr
kaum in die Sonne getraut – jetzt
genieße ich es, dass ich, zumindest
stundenweise, ganz normal leben
kann – draußen, im Licht


And then
finally, after all this time of suffering,
she got therapy that worked.
helped. A gigantic luck, because
at the moment by no means all of the
to be treated.
"On June 26, 2017, I know that.
I was given the first
Scenesse implant," she says.
And the drug worked. But
the fear of pain remained
- for now. "I spent a year
hardly trusted in the sun - now
I enjoy that I, at least.
by the hour, just normal life
can - outside, in the light

  Forum: By Share Code

odi01
Posted on: Jul 24 2019, 07:03 PM


Group: Member
Posts: 772

http://www.epp-deutschland.de/mediapool/21..._30_1_.2019.pdf
  Forum: By Share Code

4 Pages (Click to Jump) V   1 2 3 4 >

Cant find what you are looking for? Show all active topics from the last 3 months


New Posts  New Replies
No New Posts  No New Replies
Hot topic  Hot Topic (New)
No new  Hot Topic (No New)



TERMS OF USE  -  CONTACT ADMIN  -  ADVERTISING